How the PTP1B enzyme affects heart muscle thickening
Role of Protein Tyrosine Phosphatase 1B in Cardiac Hypertrophy
['FUNDING_R01'] · STATE UNIVERSITY OF NEW YORK AT ALBANY · NIH-11112535
Researchers are testing whether protecting a heart enzyme called PTP1B from oxidative damage can prevent harmful thickening of the heart muscle in people with pressure-related heart stress.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NEW YORK AT ALBANY (nih funded) |
| Locations | 1 site (ALBANY, UNITED STATES) |
| Trial ID | NIH-11112535 on ClinicalTrials.gov |
What this research studies
This project looks at why a heart-cell enzyme, PTP1B, becomes disabled by oxidative stress during pressure overload and how that leads to harmful thyroid-hormone-driven heart muscle growth. The team will use molecular studies and genetically modified mice to map how PTP1B oxidation changes signaling in heart cells and to test whether a short peptide can stop that oxidation. They will also use viral delivery methods and measure heart structure and function to see if preserving PTP1B improves heart performance. The findings aim to guide future treatments for patients with hypertrophy and related heart failure.
Who could benefit from this research
Good fit: People with pressure-overload cardiac hypertrophy or early-stage heart failure (for example from high blood pressure or valve disease) would be the most relevant candidates.
Not a fit: Patients with heart problems unrelated to hypertrophy mechanisms, such as primary electrical disorders or irreversible scarring, may not benefit directly.
Why it matters
Potential benefit: If successful, this work could point to new treatments that stop or reverse pathological heart muscle enlargement and improve heart function in people with hypertrophy-related heart failure.
How similar studies have performed: Earlier animal studies, including the investigators' mouse experiments, showed promising rescue of heart function by targeting thyroid signaling and preventing PTP1B inactivation, but human testing remains unproven.
Where this research is happening
ALBANY, UNITED STATES
- STATE UNIVERSITY OF NEW YORK AT ALBANY — ALBANY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOIVIN, BENOIT — STATE UNIVERSITY OF NEW YORK AT ALBANY
- Study coordinator: BOIVIN, BENOIT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.